Advertisement

Rheumatology International

, Volume 32, Issue 11, pp 3613–3618 | Cite as

Evaluation of the Iranian versions of the bath ankylosing spondylitis disease activity index (BASDAI), the bath ankylosing spondylitis functional index (BASFI) and the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis

  • Katayoon Bidad
  • Sasan Fallahi
  • Mahdi Mahmoudi
  • Ahmadreza Jamshidi
  • Elham Farhadi
  • Alipasha Meysamie
  • Mohammad Hossein NicknamEmail author
Original Article

Abstract

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI) are widely used instruments in assessment of patients suffering from ankylosing spondylitis (AS). The Patient Acceptable Symptom State (PASS) is regarded as a target for patients’ well-being. The aim of this study was to translate and adapt BASDAI, BASFI and PASS into the Iranian official language, Farsi, and evaluate their reliability and validity. Ninety patients with AS were included in this study. The questionnaires were translated into Farsi and back translated into English, modified until the final versions were approved with minor adaptations and the VAS was changed to numerical rating scales from 0 to 10. Forty-eight-hour test–retest agreement showed good reliability: interclass correlation coefficient (ICC) for BASDAI was 0.93 (CI at 95%, 0.90–0.95), for BASFI was 0.96 (CI at 95%, 0.94–0.97) and for PASS was 0.87 (CI at 95%, 0.79–0.92). Chronbach’s alpha was 0.95, 0.96 and 0.87 for BASDAI, BASFI and PASS, respectively. BASDAI showed a significant correlation with patient global disease activity index, nocturnal back pain, total back pain, number of swollen joints, number of enthesites, morning stiffness, Bath Ankylosing Spondylitis Global Score (BAS-G), BASFI and BASMI. A significant correlation was also found between BASFI and occiput-to-wall distance, mentum-to-sternum distance, chest expansion, finger-to-floor distance, number of swollen joints, number of enthesites, nocturnal back pain, total back pain, BAS-G, BASDAI and BASMI. Patients who answered “no” to PASS (found their condition unsatisfactory) reported significantly increased pain scores, patient global disease activity scores, BAS-G, BASDAI and BASFI scores. The results showed that the Iranian versions of BASDAI, BASFI and PASS are adequately reliable and valid in patients with AS.

Keywords

Ankylosing spondylitis BASDAI BASFI Iranian PASS 

Notes

Acknowledgments

This study was supported by a grant (89-04-40-11640) from Tehran University of Medical Sciences.

Conflict of interest

None.

Supplementary material

296_2011_2186_MOESM1_ESM.pdf (151 kb)
Supplementary material 1 (PDF 151 kb)

References

  1. 1.
    Hajjaj-Hassouni N, Burgos-Vargas R (2008) Ankylosing spondylitis and reactive arthritis in the developing world. Best Pract Res Clin Rheumatol 22(4):709–723PubMedCrossRefGoogle Scholar
  2. 2.
    Madsen OR, Rytter A, Hansen LB, Suetta C, Egsmose C (2010) Reproducibility of the Bath ankylosing spondylitis indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients. Clin Rheumatol 29(8):849–854PubMedCrossRefGoogle Scholar
  3. 3.
    Zochling J, Braun J (2007) Quality indicators, guidelines and outcome measures in ankylosing spondylitis. Clin Exp Rheumatol 25(6 Suppl 47):147–152PubMedGoogle Scholar
  4. 4.
    Yanik B, Gursel YK, Kutlay S, Ay S, Elhan AH (2005) Adaptation of the bath ankylosing spondylitis functional index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol 24(1):41–47PubMedCrossRefGoogle Scholar
  5. 5.
    Pham T, van der Heijde D, Calin A, Khan MA, van der Linden S, Bellamy N, Dougados M (2003) Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS group. Ann Rheum Dis 62(9):812–816PubMedCrossRefGoogle Scholar
  6. 6.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27(4):361–368CrossRefGoogle Scholar
  7. 7.
    Jones SD, Steiner A, Garrett SL, Calin A (1996) The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35(1):66–71PubMedCrossRefGoogle Scholar
  8. 8.
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 21(9):1694–1698PubMedGoogle Scholar
  9. 9.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21(12):2286–2291PubMedGoogle Scholar
  10. 10.
    Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21(12):2281–2285PubMedGoogle Scholar
  11. 11.
    Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A (2007) Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthr Rheum 57(1):133–139CrossRefGoogle Scholar
  12. 12.
    Dougados M, Luo MP, Maksymowych WP, Chmiel JJ, Chen N, Wong RL, Davis JC Jr, van der Heijde D (2008) Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthr Rheum 59(4):553–560CrossRefGoogle Scholar
  13. 13.
    Van Tubergen A, Debats I, Ryser L, Londono J, Burgos-Vargas R, Cardiel MH, Landewe R, Stucki G, Van Der Heijde D (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthr Rheum 47(3):242–248CrossRefGoogle Scholar
  14. 14.
    El Miedany Y, Youssef S, Mehanna A, Shebrya N, Gamra SA, El Gaafary M (2008) Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic bath ankylosing spondylitis functional index (BASFI), the bath ankylosing spondylitis disease activity index (BASDAI), and the bath ankylosing spondylitis global score (BASG). Clin Rheumatol 27(5):605–612PubMedCrossRefGoogle Scholar
  15. 15.
    Hidding A, van Santen M, De Klerk E, Gielen X, Boers M, Geenen R, Vlaeyen J, Kester A, van der Linden S (1994) Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. J Rheumatol 21(5):818–823PubMedGoogle Scholar
  16. 16.
    Zochling J (2008) Assessment and treatment of ankylosing spondylitis: current status and future directions. Curr Opin Rheumatol 20(4):398–403PubMedCrossRefGoogle Scholar
  17. 17.
    Claudepierre P, Sibilia J, Goupille P, Flipo RM, Wendling D, Eulry F, Clerc D, Berthelot JM, Vergne P, Roudot-Thoraval F, Larget-Piet B, Chevalier X (1997) Evaluation of a French version of the bath ankylosing spondylitis disease activity Index in patients with spondyloarthropathy. J Rheumatol 24(10):1954–1958PubMedGoogle Scholar
  18. 18.
    Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J (2003) Adaption and validation of the bath ankylosing spondylitis disease activity index (BASDAI) for use in Germany. Z Rheumatol 62(3):264–273PubMedGoogle Scholar
  19. 19.
    Ruof J, Sangha O, Stucki G (1999) Evaluation of a German version of the bath ankylosing spondylitis functional index (BASFI) and Dougados functional index (D-FI). Z Rheumatol 58(4):218–225PubMedCrossRefGoogle Scholar
  20. 20.
    Bonisch A, Ehlebracht-Konig I (2003) The BASDAI-D–an instrument to defining disease status in ankylosing spondylitis and related diseases. Z Rheumatol 62(3):251–263PubMedGoogle Scholar
  21. 21.
    Waldner A, Cronstedt H, Stenstrom CH (1999) The Swedish version of the bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol Suppl 111:10–16PubMedCrossRefGoogle Scholar
  22. 22.
    Cronstedt H, Waldner A, Stenstrom CH (1999) The Swedish version of the bath ankylosing spondylitis functional index. Reliability and validity. Scand J Rheumatol Suppl 111:1–9PubMedCrossRefGoogle Scholar
  23. 23.
    Heikkila S, Viitanen JV, Kautianen H, Kauppi M (2000) Evaluation of the Finnish versions of the functional indices BASFI and DFI in spondylarthropathy. Clin Rheumatol 19(6):464–469PubMedCrossRefGoogle Scholar
  24. 24.
    Cardiel MH, Londono JD, Gutierrez E, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R (2003) Translation, cross-cultural adaptation, and validation of the bath ankylosing spondylitis functional index (BASFI), the bath ankylosing spondylitis disease activity index (BASDAI) and the Dougados functional index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21(4):451–458PubMedGoogle Scholar
  25. 25.
    Kchir MM, Hamdi W, Kochbati S, Azzouz D, Daoud L, Saadellaoui K, Ghannouchi MM, Kaffel D, Hamida AB, Zouari B (2009) Validation of the Tunisian versions of bath ankylosing spondylitis functional index (BASFI) and disease activity index (BASDAI). Tunis Med 87(8):527–530PubMedGoogle Scholar
  26. 26.
    Rostom S, Benbouaaza K, Amine B, Bahiri R, Yacoub YI, Alla SAO, Abouqal R, Hajjaj-Hassouni N (2010) Psychometric evaluation of the Moroccan version of the bath ankylosing spondylitis functional index (BASFI) and bath ankylosing spondylitis disease activity index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol 29(7):781–788PubMedCrossRefGoogle Scholar
  27. 27.
    Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N (2005) A Turkish version of the Bath ankylosing spondylitis disease activity index: reliability and validity. Rheumatol Int 25(4):280–284PubMedCrossRefGoogle Scholar
  28. 28.
    Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26(4):966–970PubMedGoogle Scholar
  29. 29.
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMedGoogle Scholar
  30. 30.
    Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 45(10):1288–1293CrossRefGoogle Scholar
  31. 31.
    Baysal O, Durmus B, Ersoy Y, Altay Z, Senel K, Nas K, Ugur M, Kaya A, Gur A, Erdal A, Ardicoglu O, Tekeoglu I, Cevik R, Yildirim K, Kamanli A, Sarac AJ, Karatay S, Ozgocmen S (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int 31(6):795–800Google Scholar
  32. 32.
    Dougados M, Moore A, Yu S, Gitton X (2007) Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthr Res Ther 9(1):R11CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Katayoon Bidad
    • 1
    • 2
  • Sasan Fallahi
    • 3
  • Mahdi Mahmoudi
    • 1
    • 2
  • Ahmadreza Jamshidi
    • 3
  • Elham Farhadi
    • 2
  • Alipasha Meysamie
    • 4
  • Mohammad Hossein Nicknam
    • 1
    • 2
    Email author
  1. 1.Department of Immunology, Faculty of MedicineTehran University of Medical SciencesTehranIran
  2. 2.Molecular Immunology Research CenterTehran University of Medical SciencesTehranIran
  3. 3.Rheumatology Research CenterTehran University of Medical SciencesTehranIran
  4. 4.Community and Preventive Medicine Department, Medical FacultyTehran University of Medical SciencesTehranIran

Personalised recommendations